Drug Approval | October 23, 2023
Zhimeng Biopharma CB03 receives Orphan Drug Designation from the USFDA
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
Investment is additive to KKR’s existing health care growth strategy
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
_256_384.jpg)
GenWorks Health Introduces Braster Pro for breast screening & EVA for cervical screening in rural areas & communities
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
